ARPA-H selected UpDoc, Tempus AI and Atman Health for a new federal program designed to build FDA-authorized agentic AI tools to manage people with heart disease. The initiative, announced by the U.S. government, is aimed at turning clinical reasoning workflows into interoperable, semi-autonomous decision support. The focus on “agentic” tools signals an emphasis on systems that can coordinate tasks (such as triage, prioritization, and evidence retrieval) rather than producing a single prediction. ARPA-H’s framing highlights regulatory authorization as a key goal. For biotech and digital health developers, the program offers a benchmark for how federal funders expect data, model governance, and clinical validation to be packaged for FDA review.